{"name":"Nurix Therapeutics","slug":"nurix","ticker":"NRIX","exchange":"NASDAQ","domain":"nurixtx.com","description":"Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences,","hq":"San Francisco, CA","founded":0,"employees":"317","ceo":"Arthur T. Sands","sector":"Protein Degradation / Oncology","stockPrice":15.94,"stockChange":-0.24,"stockChangePercent":-1.48,"marketCap":"$1.6B","metrics":{"revenue":76987000,"revenueGrowth":-66.1,"grossMargin":0,"rdSpend":316903000,"netIncome":-264457000,"cash":540732032,"dividendYield":0,"peRatio":-5.6,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"NX-212 patent cliff ($0.0B at risk)","drug":"NX-212","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"NX-1607 patent cliff ($0.0B at risk)","drug":"NX-1607","type":"patent_expiry","sentiment":"negative"},{"date":"2037-06-01","label":"NX-1608 patent cliff ($0.0B at risk)","drug":"NX-1608","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Nurix Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Nurix reported net loss of $44.4 million for the fourth quarter and $173.5 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Nurix Therapeutics Announces Collaboration with Merck KGaA to Develop Protein Degradation Therapies","summary":"Nurix entered into a collaboration with Merck KGaA to develop protein degradation therapies for the treatment of cancer.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Nurix Therapeutics Announces Positive Interim Results from Phase 1/2 Clinical Trial of NX-1607","summary":"Nurix reported positive interim results from a Phase 1/2 clinical trial of NX-1607, a protein degradation therapy for the treatment of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-08","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-04-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPU3lXZ3FpYmtweTZyRi1Ea2FwNEY0RDFFOHJLajk5SkE2YmRfaWJvOXFkOUJIVkl1SkpacS1ZMW1mS25YaXdPWmQ5OUlOSl8wallZSFM2YXktOWlQbm1CUnByYzNKRlNIWGY0djY3SzJOc1U2MmV4UUlqaGJIbkZ1MEMxc09fT0VreVN0RHhJakJYLWR4TVk2NjBFTFd5NzZaWm5NeXZiUWlNdnRqWEpQN29qenNhNkFVUXBUWEdkV3R4QkF3MXNXRVhYVVlneFREQkVQS2w2bkVOYlQyal9N?oc=5","date":"2026-02-22","type":"pipeline","source":"The Motley Fool","summary":"Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - The Motley Fool","headline":"Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-30","type":"earnings","source":"simplywall.st","summary":"Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress - simplywall.st","headline":"Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOQWsxaTRKZHdTalhSWlJUYUsyLVpibzZNNzE2SjludWlxay1xQVRIT2lGOVpXUGxDOWZhdVl2UGZJbGhuZUxodk5WWlFzV2h5SXc4SXFWTkxXeDdWUmUxczMwU2I5QnlrOXpwT1BLY0NwNnhyZ3o5M0luVzZLTy12bkU0S0VMS2tocHBTc0I2SjVjbEhvUnYwZnVRRTktMXRKSjgyVXlSbE5qTlRwRmtmWGdPMmdpeUZ2TmNCeERPaXl1SXNieFRGZkNvTHA2Wl9yUmc?oc=5","date":"2026-01-14","type":"patent","source":"PR Newswire","summary":"Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - PR Newswire","headline":"Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQcnNZbDZ3TmNMZ1d1RW1sOTlTUGFvQl82NHR6SDJMckcwMjRWUWxva1RCSEVMOTNOdkdmek5jRUNIekhCOVVNQjNRSHpfSHdpbWIyOFlYSDQyU21TajlGbm5xS2lPMXo3LTk0UklVX2M2QnhMVFdVNXlmVEU3Nko3SWNSSVNnTVFtTkJ3ZVZacFFYMHFRa0ZaTDA0SjB1MGM0OUpXYzBvdmc?oc=5","date":"2025-12-08","type":"pipeline","source":"Investor's Business Daily","summary":"Could This Biotech, Up 35%, Have The Next Dupixent? - Investor's Business Daily","headline":"Could This Biotech, Up 35%, Have The Next Dupixent? - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQREJ5MjhTU1VqYkJMYmtxQi1TZ29pX3NxTVVtRjYtVFM4aG5xRkx5TG9yLXk5cDNlQTcxWVJHNnJzYVdWTUVQYUFwTjFETkVabXpGSXpGeC00bXc2WEVjMnZTSmZ0UGZDS0stYS0wdnlhQmpqczAzNy1zM25KclpuNExERzBkeDNYOExsRTkzV095YlliWFFmZ1BBMEpPal9HQWZobkphZkRiek9DS1Jma1BkajJYb1o1RGhqMFJYX0hVS0pIa3l4MWdyakthaUI4M1hwVmV3cnJacVk?oc=5","date":"2025-12-08","type":"trial","source":"TechStock²","summary":"Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025 - TechStock²","headline":"Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNS2pfZnpJWlowLVFqYnpiZkV0dlV1YW14SFBGaXY4dkRGYzJza3Z2YzJxRkhCVTN2MTdOZlpra3VmTElQdWw2MDVLblVzTW1yaXVmSUNCOERHT0NFMlFBX1BRV2RsWW1Id3lRb01EMXk2SU1ITnA1MVlKYmgwVFExcGpIczkxdjhXWHc5WnMyckpyRVE1UHhteUNfenFxQ1BMMnJyYko5bnBiZjFKeS0zNzVzZzVZSlNYbDAtTA?oc=5","date":"2025-11-10","type":"pipeline","source":"Stock Titan","summary":"Roger Dansey, M.D., ex-Pfizer and Seagen, joins Nurix (NASDAQ: NRIX) board of directors - Stock Titan","headline":"Roger Dansey, M.D., ex-Pfizer and Seagen, joins Nurix (NASDAQ: NRIX) board of directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPWVRiU3BlWGFta0tOdElJTW9RSUptU21qWDRZT0dGQUkwcjVhcXlESUJsZ1pmU250SmJPWDcxXzF2UThnZWxtc1dfeWdXSTh6cFhMSW5Hb2liSUlZMlk0NGpNX2xjUVltSHRtd1puaHZRS1BlODdqYmR5dGNRTzFVZ096eDYteV84cGhmU2xmV004djJBYi1rYXU0SGZtTDdyY3dOWndMcmppQQ?oc=5","date":"2025-07-13","type":"pipeline","source":"Seeking Alpha","summary":"Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors (NASDAQ:NRIX) - Seeking Alpha","headline":"Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors (NASDAQ:NRIX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNTzZfM1pvX2hXVDh1VERjaDJLd3B3RDJXQ2YyVkdUUTVJNDhzcDhOVFdCUFZ2dGt0c2VXTXZqYWRxeUhFbGFPTGoxRUpQbFVOMjVkYmxIWWNyTm9rdFBkd2NCdzVJNHA0Sl95YU92MlVxb0lDNnNfNGlKWEIzaTFmTHZDc2FlRE5vSU9QOXU0ZDBwN2RkN3NWSVB6RE81eGtQbm9mTnBQZ0NEWWZGNXNj?oc=5","date":"2025-06-27","type":"pipeline","source":"The Business Journals","summary":"S.F. biotech subleases former Johnson & Johnson space on Peninsula - San Francisco Business Times - The Business Journals","headline":"S.F. biotech subleases former Johnson & Johnson space on Peninsula - San Francisco Business Times","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBiZ1g2Nm95YnNyM3pTZU0zcVBEak1IWTd6RHJWaWR1WGd2VXJCV1d0RzZsOHhyc2kzNlhfV05iZ2RHanVqMndHX19QVGkyVWVPMGlJ?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"NRIX Stock Price, News & Analysis - Stock Titan","headline":"NRIX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9kbXl1Z2VJMmg4dm1abkh0QndrdFc5anlQWXlQUVhsaGd4Ny1lNGNTLThHVGQ0MGRDbHV5cWJ6RlliQWVqbDlJNTJYdHdUV3ZUYmdkSjd1T19WRVdMb0w3S2E0Zm01RVFncjFmWTVhM1Z5Y2hiSW9iWWEwSnY?oc=5","date":"2025-04-03","type":"deal","source":"The Pharma Letter","summary":"Nurix expands licensing deal with Sanofi - The Pharma Letter","headline":"Nurix expands licensing deal with Sanofi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOQ3U4Yi1tN3ZkdkFyYV9vUWJnNkVJcDQzcHdvSkNiS1Jfc2RHSTdUeVNwbmRJS1ZTOEpGRjdXZUxhcFNlRG5hZWFVZ1JJa2U4NFRvNmhEeFRHVjRSeGctQ09hZVJxT1M5anRtLTZJM3ZxWXVuUVNoMnZHVHdqejRYdjZ4SnMzaDN0WmIwQmlCR0phckd5ZGVUdXpzRUs4SFozUU5mSmdGQmhXY2lPWkxFdU1OYWFuZw?oc=5","date":"2022-10-19","type":"deal","source":"bloomberg.com","summary":"Cathie Wood Buys Little-Known Pharma Firm’s Shares for Two Weeks (NRIX) - bloomberg.com","headline":"Cathie Wood Buys Little-Known Pharma Firm’s Shares for Two Weeks (NRIX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE5teEpLQ1dvS2RtbFd1UXVuUVdxWjJnRjlIbEZBcjY0dk0yd0JOb0pueVNFNG13RHZrcld2ZDdEUDZDODFkbmExai1VZktRVmhHWGc?oc=5","date":"2020-11-22","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Nurix Therapeutics, Inc. (NRIX) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Nurix Therapeutics, Inc. (NRIX) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"NX-212","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0},{"drugName":"NX-1607","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0},{"drugName":"NX-1608","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2037-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Bristol Myers Squibb","Merck & Co."],"therapeuticFocus":["Oncology","Protein Degradation"],"financials":{"source":"sec_edgar+yahoo","revenue":76987000,"revenuePeriod":"2023-11-30","revenueHistory":[{"value":76987000,"period":"2023-11-30"},{"value":38627000,"period":"2022-11-30"},{"value":38627000,"period":"2022-11-30"},{"value":29750000,"period":"2021-11-30"},{"value":29750000,"period":"2021-11-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":316903000,"rdSpendHistory":[{"period":"2025-11-30","value":316903000},{"period":"2024-11-30","value":221632000},{"period":"2023-11-30","value":189148000},{"period":"2022-11-30","value":184497000}],"sgaSpend":52743000,"operatingIncome":-285666000,"operatingIncomeHistory":[{"period":"2025-11-30","value":-285666000},{"period":"2024-11-30","value":-213027000},{"period":"2023-11-30","value":-155063000},{"period":"2022-11-30","value":-183867000}],"netIncome":-264457000,"netIncomeHistory":[{"period":"2025-11-30","value":-264457000},{"period":"2024-11-30","value":-193569000},{"period":"2023-11-30","value":-143948000},{"period":"2022-11-30","value":-180360000}],"eps":-3.05,"epsHistory":[{"period":"2025-11-30","value":-3.05},{"period":"2024-11-30","value":-2.88},{"period":"2023-11-30","value":-2.65},{"period":"2022-11-30","value":-3.71}],"cash":246960000,"cashHistory":[{"period":"2025-11-30","value":246960000},{"period":"2024-11-30","value":109997000},{"period":"2023-11-30","value":54627000},{"period":"2022-11-30","value":64474000}],"totalAssets":688135000,"totalLiabilities":149388000,"totalDebt":55730000,"equity":538747000,"operatingCashflow":-249465000,"operatingCashflowHistory":[{"period":"2025-11-30","value":-249465000},{"period":"2024-11-30","value":-172584000},{"period":"2023-11-30","value":-81365000},{"period":"2022-11-30","value":-159807000}],"capex":-14002000,"capexHistory":[{"period":"2025-11-30","value":-14002000},{"period":"2024-11-30","value":-9273000},{"period":"2023-11-30","value":-8401000},{"period":"2022-11-30","value":-12244000}],"freeCashflow":-263467000,"dividendsPaid":null,"buybacks":null,"employees":317,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":14610000,"ebit":-92495000,"ebitda":-88719000,"period":"2026-02-28","revenue":6252000,"epsBasic":-0.79,"netIncome":-87174000,"rdExpense":84137000,"epsDiluted":-0.79,"grossProfit":null,"operatingIncome":-92495000},{"sga":13648000,"ebit":-83095000,"ebitda":-78464000,"period":"2025-11-30","revenue":13577000,"epsBasic":-0.82,"netIncome":-78221000,"rdExpense":83024000,"epsDiluted":-0.82,"grossProfit":null,"operatingIncome":-83095000},{"sga":13159000,"ebit":-91385000,"ebitda":-86385000,"period":"2025-08-31","revenue":7894000,"epsBasic":-1.03,"netIncome":-86421000,"rdExpense":86120000,"epsDiluted":-1.03,"grossProfit":null,"operatingIncome":-91385000},{"sga":14282000,"ebit":-48322000,"ebitda":-43225000,"period":"2025-05-31","revenue":44056000,"epsBasic":-0.52,"netIncome":-43464000,"rdExpense":78096000,"epsDiluted":-0.52,"grossProfit":null,"operatingIncome":-48322000},{"sga":11654000,"ebit":-62864000,"ebitda":-58736000,"period":"2025-02-28","revenue":18453000,"epsBasic":-0.67,"netIncome":-56351000,"rdExpense":69663000,"epsDiluted":-0.67,"grossProfit":null,"operatingIncome":-62864000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-11-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":15.94,"previousClose":16.18,"fiftyTwoWeekHigh":22.5,"fiftyTwoWeekLow":8.2,"fiftyTwoWeekRange":"8.195 - 22.5","fiftyDayAverage":15.96,"twoHundredDayAverage":14.3,"beta":1.88,"enterpriseValue":1191028992,"forwardPE":-5.6,"priceToBook":3.43,"priceToSales":22.96,"enterpriseToRevenue":16.59,"enterpriseToEbitda":-3.88,"pegRatio":0,"ebitda":-307311008,"ebitdaMargin":0,"freeCashflow":-145462624,"operatingCashflow":-260292000,"totalDebt":58655000,"debtToEquity":12.2,"currentRatio":6.01,"returnOnAssets":-31.5,"returnOnEquity":-61.4,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":17,"targetMeanPrice":30.24,"targetHighPrice":41,"targetLowPrice":23,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.1,"institutionHeldPercent":113,"sharesOutstanding":103405813,"floatShares":88208261,"sharesShort":19201109,"shortRatio":17.47,"shortPercentOfFloat":18.6,"epsTrailing":-3.17,"epsForward":-2.86,"revenuePerShare":0.77,"bookValue":4.65,"officers":[{"age":63,"name":"Dr. Arthur T. Sands M.D., Ph.D.","title":"CEO, President & Director"},{"age":58,"name":"Mr. Johannes  Van Houte","title":"Chief Financial Officer"},{"age":54,"name":"Dr. Gwenn M. Hansen Ph.D.","title":"Chief Scientific Officer"},{"age":60,"name":"Dr. Christine  Ring J.D., Ph.D.","title":"Chief Legal Officer, Secretary & Chief Compliance Officer"},{"age":null,"name":"Dr. John  Kuriyan Ph.D.","title":"Founder & Member of Scientific Advisory Board"},{"age":null,"name":"Dr. Arthur  Weiss M.D., Ph.D.","title":"Founder & Member of Scientific Advisory Board"},{"age":null,"name":"Rita  Kwong","title":"Senior Accounting Manager"},{"age":null,"name":"Dr. Pasit  Phiasivongsa Ph.D.","title":"Chief Technical Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.nurixtx.com","phone":"415 660 5320"}}